Predicting response to cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer: transcriptomic features outrank genomic biomarkers - Acedo-Terrades, Ariadna; Rodriguez-Vida, Alejo; Buisan, Oscar; Bódalo-Torruella, Marta; Gabarrós, Maria; Clarós, Miquel; Juanpere, Nuria; Lorenzo, Marta; Vázquez Montes de Oca, Sergio; Rios-Hoyo, Alejandro; Carrato Moñino, Cristina; Sanhueza, Tamara; et al. (medRxiv, 2024)
Muscle-invasive bladder cancer (MIBC) is associated with poor predictability of response to cisplatin-based neoadjuvant chemotherapy (NAC). Consequently, the benefit of NAC remains unclear for many patients due to the lack of reliable biomarkers predicting treatment response. In order to identify biomarkers and build an integrated and highly accurate model to predict NAC response, we performed a comprehensive transcriptomic and genomic profiling on tumors from 100 MIBC patients. Our results showed that the expression of the top genes associated with response, as well as the expression of growth factor genes and cell cycle regulators are highly correlated with NAC response. Most importantly, we found a novel signature related to the WNT signaling pathway that alone was highly correlated with NAC response and showed high accuracy in predicting NAC response (AUC=0.76). Additionally, mutations in the DNAH family genes (DNAH8, DNAH6 and DNAH10) and deletion in KDM6A were also highly correlated with NAC response. Using our comprehensive molecular analysis as a backbone, we developed two machine learning (ML) models, one incorporating both transcriptomic and genomic features (RF-RW), and the other using only transcriptomic data (RF-R). Both models demonstrated promising performance (AUC=0.82) as predictive models of response to NAC in MIBC. RF-RW and RF-R, after external validation, could potentially change the management of MIBC patients by selecting ideal candidates for NAC.Competing Interest StatementPotential conflicts of interest: J. Bellmunt has served in consulting or advisory roles for Astellas Pharma, AstraZeneca/MedImmune, Bristol Myers Squibb, Genentech, Novartis, Pfizer, Pierre Fabre, and the healthcare business of Merck KGaA, Darmstadt, Germany; has received travel and accommodation expenses from Ipsen, Merck & Co., Kenilworth, NJ, and Pfizer; reports patents, royalties, other intellectual property from UpToDate; reports stock and other ownership interests in Rainier Therapeutics; has received honoraria from UpToDate; and has received institutional research funding from Millennium, Pfizer, Sanofi, and the healthcare business of Merck KGaA, Darmstadt, Germany. A. Rodriguez-Vida has served in consulting or advisory roles for Astellas Pharma, Bristol Myers Squibb, Novartis, Pfizer, Johnson&Johnson, Merck, Bayer, MSD, Ipsen; has received travel and accommodation expenses from Ipsen, Merck, Johnson&Johnson and Bayer.Funding StatementThe work was supported by Project PI19/00004 and grant FI20/00095, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; 2021SGR00042 by Generalitat de CatalunyaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comite Etica de la Investigacio de l Hospital Universitari Germans Trias i Pujol Comite Etico de Investigacion Clinica del Hospital del MarI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes